Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
211 articles
October 202624
Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.
RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…
The perceptions of hematopoietic stem cell transplantation decision-making in patients with hematologic malignancies: a qualitative systematic review.
This qualitative systematic review synthesized research on how patients with hematologic malignancies perceive decisions about hematopoietic stem cell transplantation (HSCT).
Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma.
This phase 1 dose-escalation trial evaluated BCMA-directed CAR T-cell therapy MCARH125 alone or infused concurrently with GPRC5D-directed MCARH109 in patients with relapsed or refractory multiple myeloma.
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial.
The multicenter phase 1/2 CRC01-01 trial evaluated anbalcabtagene autoleucel, a CD19 CAR T-cell therapy with PD-1 and TIGIT knockdown, in patients with relapsed or refractory large B-cell lymphoma.
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.
The multicenter randomized RuxoBEAT trial compared first-line ruxolitinib (RUX) with best available therapy (BAT) in patients with polycythemia vera.
The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.
This Cochrane systematic review and meta-analysis assessed allogeneic stem cell transplantation (alloSCT) for adults with mature T-cell lymphomas (MTCL), as first-line or salvage treatment.
Ruxolitinib for the treatment of pediatric acute and chronic steroid-refractory graft-versus-host disease: Efficacy, safety, and outcomes.
This single-center retrospective study assessed ruxolitinib in children under 18 years with steroid-refractory graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study.
This multicenter, single-arm phase 2 study evaluated intravenous ifupinostat monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapy lines.
Non-Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis.
This systematic review and meta-analysis, supplemented by a pharmacovigilance analysis of FAERS, assessed non-relapse mortality (NRM) and other toxicities with bispecific antibodies in relapsed/refractory hematologic…
Local ancestry-aware genome-wide meta-analysis uncovers novel genetic loci for sickle cell disease nephropathy.
This local ancestry-aware genome-wide association meta-analysis examined estimated glomerular filtration rate in participants from two well-characterized adult sickle cell disease cohorts, seeking genetic loci…
Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4.
This open-label extension study evaluated every-2-week (Q2W) denecimig prophylaxis in patients aged ≥12 years with hemophilia A, with or without inhibitors, who had previously received denecimig in a phase 2 study and…
Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis.
This systematic review and reconstructed individual patient data meta-analysis assessed whether leukemia stem cell (LSC) measurements predict outcomes in patients with acute myeloid leukemia at diagnosis or in…
Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.
Bacterial infections and antibiotic susceptibility in children with sickle-cell anemia on malaria chemoprevention using Dihydroartemisinin-piperaquine (DP) or Sulfadoxine-pyrimethamine (SP) in Uganda.
This analysis nested within a randomized, double-blind trial assessed bacterial infections and antimicrobial resistance among Ugandan children aged 6 months to 15 years with sickle-cell anemia receiving weekly…
TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
TRANSFORM-1 was a multicentre, randomised phase 3 trial comparing navitoclax plus ruxolitinib with placebo plus ruxolitinib in Janus kinase inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis.
A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis.
This prospective, multicentre phase 2 trial evaluated daratumumab monotherapy in previously untreated patients with measurable AL amyloidosis and advanced cardiac stage IIIB disease; patients with inadequate response…
Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).
This Phase I randomised controlled trial programme evaluated two mechanistically distinct factor XI/FXIa monoclonal antibodies as potential anticoagulants, using in vitro assays, nonhuman primates and healthy…
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.
This systematic review and network meta-analysis compared T-cell-redirecting regimens in randomized phase 3 trials involving patients with multiple myeloma after at least one prior line.
Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial.
The ACCESS trial evaluated infection burden in 268 adult patients undergoing HLA-mismatched unrelated donor hematopoietic cell transplantation (HCT) with posttransplant cyclophosphamide (PTCy) for graft-versus-host…
Efficacy and safety of erythrocytapheresis in chronic mountain sickness: a randomised controlled trial protocol (ESCAPE-CMS).
This randomized controlled trial protocol investigates the efficacy and safety of erythrocytapheresis in patients with chronic mountain sickness (CMS), a condition affecting over 4 million individuals at high altitudes.
Interference of iron deficiency in glycated hemoglobin testing and its clinical implications: a systematic review and meta-analysis.
This systematic review and meta-analysis evaluated the impact of iron deficiency anemia (IDA) and latent iron deficiency (LID) on glycated hemoglobin (HbA1c) concentrations.
N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial.
This double-blind randomized controlled trial evaluated the efficacy of N-acetylcysteine (NAC) mouthwash in preventing oral mucositis (OM) in 106 hematopoietic cell transplant (HCT) recipients.
Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.
The phase 3 MORPHO trial evaluated the efficacy of gilteritinib versus placebo in post-hematopoietic cell transplantation (HCT) for FLT3-ITD AML patients.
Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.
This phase 3 randomized trial evaluated the efficacy of felzartamab combined with lenalidomide-dexamethasone versus lenalidomide-dexamethasone alone in Chinese patients with relapsed or refractory multiple myeloma.
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.